Its downregulation is associated with imatinib-resistance and induction of the epithelial-mesenchymal transition (EMT) in GBM—effects mediated by the corresponding upregulation of another of its targets, SNAI2 [140]. The gene discussed is SNAI2; the disease is glioblastoma.